John M. Capek, Executive Vice President at ABBOTT LABORATORIES (ABT), sold 34,292 shares at $45.61 ($1.6M) on 2015-02-04, disclosed to the SEC on 2015-02-06.
Scheduled sale ($1.6M) by Executive Vice President under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $45.57 | 100 | $5K | 0.3% |
| 2 | $45.58 | 100 | $5K | 0.3% |
| 3 | $45.58 | 1,400 | $64K | 4.1% |
| 4 | $45.59 | 1,600 | $73K | 4.7% |
| 5 | $45.60 | 200 | $9K | 0.6% |
| 6 | $45.60 | 2,300 |
| $105K |
| 6.7% |
| 7 | $45.61 | 400 | $18K | 1.2% |
| 8 | $45.61 | 1,300 | $59K | 3.8% |
| 9 | $45.62 | 805 | $37K | 2.3% |
| 10 | $45.63 | 700 | $32K | 2.0% |
| 11 | $45.63 | 300 | $14K | 0.9% |
| 12 | $45.64 | 1,700 | $78K | 5.0% |
| 13 | $45.65 | 200 | $9K | 0.6% |
| 14 | $45.65 | 2,700 | $123K | 7.9% |
| 15 | $45.66 | 3,987 | $182K | 11.6% |
| 16 | $45.66 | 100 | $5K | 0.3% |
| 17 | $45.66 | 500 | $23K | 1.5% |
| 18 | $45.67 | 2,500 | $114K | 7.3% |
| 19 | $45.67 | 700 | $32K | 2.0% |
| 20 | $45.68 | 900 | $41K | 2.6% |
| 21 | $45.68 | 2,700 | $123K | 7.9% |
| 22 | $45.68 | 100 | $5K | 0.3% |
| 23 | $45.69 | 2,600 | $119K | 7.6% |
| 24 | $45.69 | 100 | $5K | 0.3% |
| 25 | $45.69 | 600 | $27K | 1.8% |
| 26 | $45.70 | 100 | $5K | 0.3% |
| 27 | $45.70 | 2,500 | $114K | 7.3% |
| 28 | $45.71 | 600 | $27K | 1.8% |
| 29 | $45.71 | 2,500 | $114K | 7.3% |
| Total | $45.66 avg | 34,292 | $1.6M | 100% |
| Filing → |
| ABT | SELL | 2020-04-23 | $9.6M | — | Filing → |
| ABT | SELL | 2019-06-21 | $4.0M | — | Filing → |
| ABT | SELL | 2018-07-26 | $4.2M | — | Filing → |